Renal Involvement in Familial Mediterranean Fever
Yes, patients with FMF can develop renal involvement, most critically in the form of AA amyloidosis, which represents the most serious complication and can progress to end-stage renal disease if inflammation is not adequately controlled.
Primary Renal Complication: AA Amyloidosis
The most significant renal involvement in FMF is AA amyloidosis, which develops due to chronic, inadequately suppressed inflammation 1. This occurs primarily in patients who are:
- Resistant to colchicine treatment
- Non-adherent to colchicine therapy
- Have ongoing subclinical inflammation despite treatment
The target in managing AA amyloidosis is complete and sustained control of biochemical inflammation, measured by serum amyloid A (SAA) or CRP when SAA is unavailable 1. Treatment must be intensified using maximal tolerated colchicine doses supplemented with biologics as required.
Monitoring for Subclinical Renal Involvement
Even without overt amyloidosis, FMF patients require vigilant monitoring:
- Monitor proteinuria and SAA levels regularly to detect subclinical inflammation 1
- Renal hemodynamic changes can be detected by Doppler ultrasonography even before clinical manifestations appear 2
- Serum cystatin C may serve as an early marker, with a proposed cutoff of 876.5 pg/mL for screening renal involvement 3
Prevalence and Risk Factors
Research demonstrates variable rates of renal involvement:
- Pediatric studies show 6.9% with non-amyloidosis renal involvement and 1.2% with biopsy-proven amyloidosis 4
- Adult populations show 22.2% with renal involvement manifested as proteinuria (21.3%) and/or renal impairment 5
Key risk factors include:
- M694V mutation (increases risk 2.6-fold for amyloidosis and 1.7-fold for other renal involvement) 4
- Colchicine resistance (increases risk 33-fold for amyloidosis and 25-fold for other renal involvement) 4
- Delayed diagnosis 4
- Homozygous M694V genotype shows earlier disease onset and more severe manifestations 6
Critical Management Considerations
In patients with decreased renal function, colchicine toxicity risk is substantially elevated 1. Therefore:
- Monitor serum creatine kinase concentrations carefully
- Reduce colchicine dose accordingly
- Watch for signs of colchicine toxicity
The therapeutic approach must be aggressive when renal involvement is detected, as poorly controlled FMF perpetuates the inflammatory cycle leading to progressive amyloidosis and potential renal failure 1, 7.